These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36689854)

  • 21. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
    Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
    J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for
    De Benedetto I; Shbaklo N; Vicentini C; Zotti CM; De Rosa FG; Corcione S
    Microorganisms; 2023 Apr; 11(5):. PubMed ID: 37317076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies.
    Di Bella S; Giacobbe DR; Maraolo AE; Viaggi V; Luzzati R; Bassetti M; Luzzaro F; Principe L
    J Glob Antimicrob Resist; 2021 Jun; 25():268-281. PubMed ID: 33895414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central nervous system adverse events of ceftazidime/avibactam: A retrospective study using Food and Drug Administration Adverse Event Reporting System.
    Guo X; Guo M; Li J; Cui X
    J Clin Pharm Ther; 2022 Dec; 47(12):2369-2372. PubMed ID: 36369970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points.
    Torres A; Rank D; Melnick D; Rekeda L; Chen X; Riccobene T; Critchley IA; Lakkis HD; Taylor D; Talley AK
    Open Forum Infect Dis; 2019 Apr; 6(4):ofz149. PubMed ID: 31041348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.
    Xiong L; Wang X; Wang Y; Yu W; Zhou Y; Chi X; Xiao T; Xiao Y
    WIREs Mech Dis; 2022 Nov; 14(6):e1571. PubMed ID: 35891616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
    Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients.
    Tsolaki V; Mantzarlis K; Mpakalis A; Malli E; Tsimpoukas F; Tsirogianni A; Papagiannitsis C; Zygoulis P; Papadonta ME; Petinaki E; Makris D; Zakynthinos E
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa.
    Corbella L; Boán J; San-Juan R; Fernández-Ruiz M; Carretero O; Lora D; Hernández-Jiménez P; Ruiz-Ruigómez M; Rodríguez-Goncer I; Silva JT; López-Medrano F; Lizasoain M; Villa J; Caro-Teller JM; Aguado JM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106517. PubMed ID: 34990760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
    Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis.
    Nguyen CP; Dan Do TN; Bruggemann R; Ten Oever J; Kolwijck E; Adang EMM; Wertheim HFL
    Int J Antimicrob Agents; 2019 Dec; 54(6):790-797. PubMed ID: 31284041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
    Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
    Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
    BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
    Gu J; Xu J; Zuo TT; Chen YB
    J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018.
    Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
    Braz J Infect Dis; 2022; 26(3):102369. PubMed ID: 35618040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.